Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Botensilimab, Balstilimab and Regorafenib in Patients With Microsatellite Stable Colorectal Cancer

NCT06575725 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT06575725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06575725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Botensilimab, Balstilimab and Regorafenib in Patients With Microsatellite Stable Colorectal Cancer
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Withdrawn
Start date
November 1, 2024
Completion date
January 28, 2027
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colon adenocarcinoma, advanced colorectal adenocarcinoma, advanced rectal adenocarcinoma, metastatic colon adenocarcinoma, metastatic colorectal adenocarcinoma, metastatic rectal adenocarcinoma, stage iii colon cancer ajcc v8, stage iii colorectal cancer ajcc v8, stage iii rectal cancer ajcc v8, stage iv colon cancer ajcc v8, stage iv colorectal cancer ajcc v8, stage iv rectal cancer ajcc v8